Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,673.09
(
-0.64%
)
US TECH 100
24,005.60
(
-0.53%
)
Dow Jones
46,575.97
(
-0.89%
)
Brent Oil
103.80
(
3.13%
)
Bitcoin
71,873.08
(
-2.80%
)
News Focus
News Focus
Post# of 19309
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 08/13/2007 7:14:47 AM

Monday, August 13, 2007 7:14:47 AM

Post# of 19309
How is Novo Nordisk preparing for NovoSeven patent expiration?

NVO’s blockbuster rFVIIa drug, NovoSeven, goes off-patent in the US—its largest market—in 2011. NVO has a two-pronged approach to deal with this predicament:

1. A fast-acting FVIIa analogue called NN1731, which is in phase-2:
http://seloken.com/secNewsItem/Variant-rFVIIa-more-active-than-NovoSeven.aspx

2. A long-acting FVIIa analogue called NN7128 based on pegylation technology from NTEC, which is in phase-1 (#msg-21139054).

Clearly, both of these programs warrant close attention by GTC investors. However, these two drug candidates are FVIIa analogues, not FVIIa per se. Thus, they would seem to incur a higher regulatory risk than the FVIIa program from GTC and partner, LFB.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now